spacer
spacer

PDBsum entry 2dv0

Go to PDB code: 
protein ligands links
Oxidoreductase PDB id
2dv0

 

 

 

 

Loading ...

 
JSmol PyMol  
Contents
Protein chain
314 a.a. *
Ligands
NAP
ZST
Waters ×223
* Residue conservation analysis
PDB id:
2dv0
Name: Oxidoreductase
Title: Human aldose reductase complexed with zopolrestat after 6 days soaking(6days_soaked_2)
Structure: Aldose reductase. Chain: a. Synonym: ar, aldehyde reductase. Engineered: yes
Source: Homo sapiens. Human. Organism_taxid: 9606. Expressed in: escherichia coli. Expression_system_taxid: 562.
Resolution:
1.62Å     R-factor:   0.187     R-free:   0.270
Authors: H.Steuber,A.Heine,G.Klebe
Key ref:
H.Steuber et al. (2006). Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions. J Mol Biol, 363, 174-187. PubMed id: 16952371 DOI: 10.1016/j.jmb.2006.08.011
Date:
28-Jul-06     Release date:   03-Oct-06    
PROCHECK
Go to PROCHECK summary
 Headers
 References

Protein chain
Pfam   ArchSchema ?
P15121  (ALDR_HUMAN) -  Aldo-keto reductase family 1 member B1 from Homo sapiens
Seq:
Struc:
316 a.a.
314 a.a.*
Key:    PfamA domain  Secondary structure  CATH domain
* PDB and UniProt seqs differ at 1 residue position (black cross)

 Enzyme reactions 
   Enzyme class 1: E.C.1.1.1.21  - aldose reductase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction:
1. an alditol + NAD+ = an aldose + NADH + H+
2. an alditol + NADP+ = an aldose + NADPH + H+
alditol
+
NAD(+)
Bound ligand (Het Group name = NAP)
matches with 91.67% similarity
= aldose
+ NADH
+ H(+)
alditol
+
NADP(+)
Bound ligand (Het Group name = NAP)
corresponds exactly
= aldose
+ NADPH
+ H(+)
   Enzyme class 2: E.C.1.1.1.300  - NADP-retinol dehydrogenase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: all-trans-retinol + NADP+ = all-trans-retinal + NADPH + H+
all-trans-retinol
+
NADP(+)
Bound ligand (Het Group name = NAP)
corresponds exactly
= all-trans-retinal
+ NADPH
+ H(+)
   Enzyme class 3: E.C.1.1.1.372  - D/L-glyceraldehyde reductase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction:
1. glycerol + NADP+ = L-glyceraldehyde + NADPH + H+
2. glycerol + NADP+ = D-glyceraldehyde + NADPH + H+
glycerol
+
NADP(+)
Bound ligand (Het Group name = NAP)
corresponds exactly
= L-glyceraldehyde
+ NADPH
+ H(+)
glycerol
+
NADP(+)
Bound ligand (Het Group name = NAP)
corresponds exactly
= D-glyceraldehyde
+ NADPH
+ H(+)
   Enzyme class 4: E.C.1.1.1.54  - allyl-alcohol dehydrogenase.
[IntEnz]   [ExPASy]   [KEGG]   [BRENDA]
      Reaction: allyl alcohol + NADP+ = acrolein + NADPH + H+
allyl alcohol
+
NADP(+)
Bound ligand (Het Group name = NAP)
corresponds exactly
= acrolein
+ NADPH
+ H(+)
Note, where more than one E.C. class is given (as above), each may correspond to a different protein domain or, in the case of polyprotein precursors, to a different mature protein.
Molecule diagrams generated from .mol files obtained from the KEGG ftp site

 

 
    reference    
 
 
DOI no: 10.1016/j.jmb.2006.08.011 J Mol Biol 363:174-187 (2006)
PubMed id: 16952371  
 
 
Expect the unexpected or caveat for drug designers: multiple structure determinations using aldose reductase crystals treated under varying soaking and co-crystallisation conditions.
H.Steuber, M.Zentgraf, C.Gerlach, C.A.Sotriffer, A.Heine, G.Klebe.
 
  ABSTRACT  
 
In structure-based drug design, accurate crystal structure determination of protein-ligand complexes is of utmost importance in order to elucidate the binding characteristics of a putative lead to a given target. It is the starting point for further design hypotheses to predict novel leads with improved properties. Often, crystal structure determination is regarded as ultimate proof for ligand binding providing detailed insight into the specific binding mode of the ligand to the protein. This widely accepted practise relies on the assumption that the crystal structure of a given protein-ligand complex is unique and independent of the protocol applied to produce the crystals. We present two examples indicating that this assumption is not generally given, even though the composition of the mother liquid for crystallisation was kept unchanged: Multiple crystal structure determinations of aldose reductase complexes obtained under varying crystallisation protocols concerning soaking and crystallisation exposure times were performed resulting in a total of 17 complete data sets and ten refined crystal structures, eight in complex with zopolrestat and two complexed with tolrestat. In the first example, a flip of a peptide bond is observed, obviously depending on the crystallisation protocol with respect to soaking and co-crystallisation conditions. This peptide flip is accompanied by a rupture of an H-bond formed to the bound ligand zopolrestat. The indicated enhanced local mobility of the complex is in agreement with the results of molecular dynamics simulations. As a second example, the aldose reductase-tolrestat complex is studied. Unexpectedly, two structures could be obtained: one with one, and a second with four inhibitor molecules bound to the protein. They are located in and near the binding pocket facilitated by crystal packing effects. Accommodation of the four ligand molecules is accompanied by pronounced shifts concerning two helices interacting with the additional ligands.
 
  Selected figure(s)  
 
Figure 3.
Figure 3. Selected conformational snapshots obtained from the MD simulation of the ALR2–zopolrestat complex are represented for the residues Cys298, Ala299, and Leu300. These snapshots suggest enhanced mobility in this region: while the conformations shown in green or magenta enable H-bond formation to the ligand's N3, this H-bond is ruptured in the conformations coloured in light blue or yellow. The inhibitor as observed in 10days_cocryst is represented as grey sticks after superimposing this crystal structure with the MD snapshots using a C^α-fit.
Figure 6.
Figure 6. TIM-barrel of ALR2 represented as a tube, emphasizing the local mobility with respect to the refined B-factors. The tube is coloured by B-factor: blue regions correspond to low temperature factors, whereas green, yellow and red colour characterize regions of subsequently increasing B-factor. In particular, dark blue represents B-values in the single-digit range, whereas red depicts regions with average B-factors of 40 Å^2 and higher. Additionally, gain of temperature factor is represented by an increasing diameter of the tube. The inhibitor zopolrestat is shown in magenta: (a) represents the corresponding tube representation for 10days_cocryst, in (b) the one for 6days_soaked_1 is given. Note the remarkable gain of local mobility within the C-terminal loop region lining the ligand binding pocket observed in 6days_soaked_1 ( vert, similar 31 Å^2, shown in yellow) compared to 10days_cocryst ( vert, similar 15 Å^2, represented in light blue). This comparison suggests that extended soaking exposure times provoke increasing mobility with respect to distinct regions represented by higher B-factors.
 
  The above figures are reprinted by permission from Elsevier: J Mol Biol (2006, 363, 174-187) copyright 2006.  
  Figures were selected by the author.  

Literature references that cite this PDB file's key reference

  PubMed id Reference
22659875 L.Chen, J.Wang, Y.Y.Zhang, S.F.Yan, D.Neumann, U.Schlattner, Z.X.Wang, and J.W.Wu (2012).
AMP-activated protein kinase undergoes nucleotide-dependent conformational changes.
  Nat Struct Mol Biol, 19, 716-718.
PDB codes: 4eag 4eai 4eaj 4eak 4eal
21376648 A.H.Al-Nadaf, and M.O.Taha (2011).
Discovery of new renin inhibitory leads via sequential pharmacophore modeling, QSAR analysis, in silico screening and in vitro evaluation.
  J Mol Graph Model, 29, 843-864.  
21482446 B.O.Al-Najjar, H.A.Wahab, T.S.Tengku Muhammad, A.C.Shu-Chien, N.A.Ahmad Noruddin, and M.O.Taha (2011).
Discovery of new nanomolar peroxisome proliferator-activated receptor γ activators via elaborate ligand-based modeling.
  Eur J Med Chem, 46, 2513-2529.  
19275144 C.Mulakala, and Y.N.Kaznessis (2009).
Path-integral method for predicting relative binding affinities of protein-ligand complexes.
  J Am Chem Soc, 131, 4521-4528.  
17229415 I.M.Kapetanovic (2008).
Computer-aided drug discovery and development (CADDD): in silico-chemico-biological approach.
  Chem Biol Interact, 171, 165-176.  
18785728 P.Cozzini, G.E.Kellogg, F.Spyrakis, D.J.Abraham, G.Costantino, A.Emerson, F.Fanelli, H.Gohlke, L.A.Kuhn, G.M.Morris, M.Orozco, T.A.Pertinhez, M.Rizzi, and C.A.Sotriffer (2008).
Target flexibility: an emerging consideration in drug discovery and design.
  J Med Chem, 51, 6237-6255.  
17896038 C.B.Aakeröy, J.Desper, and M.M.Smith (2007).
Constructing, deconstructing, and reconstructing ternary supermolecules.
  Chem Commun (Camb), (), 3936-3938.  
18087047 O.Gallego, F.X.Ruiz, A.Ardèvol, M.Domínguez, R.Alvarez, A.R.de Lera, C.Rovira, J.Farrés, I.Fita, and X.Parés (2007).
Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10.
  Proc Natl Acad Sci U S A, 104, 20764-20769.
PDB code: 1zua
The most recent references are shown first. Citation data come partly from CiteXplore and partly from an automated harvesting procedure. Note that this is likely to be only a partial list as not all journals are covered by either method. However, we are continually building up the citation data so more and more references will be included with time. Where a reference describes a PDB structure, the PDB codes are shown on the right.

 

spacer

spacer